Geonistin

Quick links to important sections

Geonistin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Geonistin

Quick Facts

Property Description
Active ingredient Nystatin and Oxytetracycline Hydrochloride
Form Vaginal tablets
Pharmacological class Combination Antifungal and Broad-spectrum Antibiotic
Common use Local treatment of mixed infections
Origin Chemical (semi-synthetic and naturally-derived components)

What Type of Medicine is Geonistin?

Geonistin is defined as a proprietary fixed dose combination medicinal product, specifically a vaginal tablet intended for topical administration. This formulation is distinctive because it combines two active agents—an antifungal and an antibacterial—in a single, stable dose, designed to streamline local therapy compared to using sequential or separate monotherapy products. The medicinal product's classification is a blend of a Polyene Antifungal Agent and a Broad-spectrum Antibiotic belonging to the Tetracycline class.

Composition and Origin of Geonistin's Active Ingredients

The active core comprises the international non-proprietary names (INN): Nystatin and Oxytetracycline Hydrochloride. Nystatin, which acts as the antifungal component, is derived from a natural source, while Oxytetracycline is a semi-synthetic compound within the Tetracycline-class Antimicrobials. The vaginal tablet form is designed as a specialized local treatment formulation, ensuring the simultaneous delivery of both agents directly to the target area, which is a key differentiating feature for addressing complex local pathology.

General Therapeutic Purpose of the Combination

The purpose of this fixed combination is to provide a comprehensive local treatment approach, targeting both major microbial classes in one application. The dual mechanism of action allows the product to address both the yeast component (via Nystatin) and the bacterial component (via Oxytetracycline) of potential infections simultaneously. This strategy of combining agents is recognized for streamlining therapy for mixed infections, offering a practical benefit in providing relief from associated symptoms.

What side effects are possible with Geonistin?

Possible side effects and safety information

The safety profile for this fixed-dose combination product containing Nystatin and Oxytetracycline is largely characterized by localized reactions due to its topical vaginal administration. Regulatory documents classify the most frequent adverse reactions as those occurring at the site of application.

Frequency Category Common Adverse Reactions
Common to Uncommon Local burning sensation, pruritus (itching), vaginal irritation, localized edema (swelling), or general discomfort.
Rare Systemic allergic manifestations, including rash, urticaria, or contact dermatitis.

These effects primarily involve the Reproductive System and Breast Disorders and Skin and Subcutaneous Tissue Disorders system-organ classes. The occurrence of local reactions, such as burning and irritation, may be more pronounced at the start of therapy.

Safety Constraints and Considerations

Official labeling includes high-level constraints related to the drug's components. The product is contraindicated in individuals with a known hypersensitivity to Nystatin, Oxytetracycline, or other agents within the polyene antifungal or tetracycline drug classes.

Due to the Oxytetracycline component, which belongs to the Tetracycline class, specific safety considerations exist for special populations. The systemic use of tetracyclines has a documented risk of fetal toxicity, specifically affecting skeletal and dental development, leading to constraints on its use during the second and third trimesters of pregnancy. Furthermore, prolonged or repeated use of any antimicrobial agent carries the regulatory-documented risk of superinfection, which is the overgrowth of non-susceptible microorganisms.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Geonistin, a vaginal tablet containing Nystatin and Oxytetracycline, defines the overdose risk based on the components' absorption characteristics. Due to the negligible systemic absorption of the Nystatin component and the minimal expected absorption from the topical route, no systemic toxicity is expected following an overdose. The documented clinical manifestations are limited, primarily relating to accidental large-quantity oral ingestion.


Documented Overdose Manifestations

Presentation Description (Based on Regulatory Labeling)
Gastrointestinal Overdose may present with nausea and gastrointestinal upset, primarily associated with oral doses of Nystatin in excess of five million units daily.
Systemic Risk No specific severe or life-threatening systemic outcomes are formally documented for this local formulation.

Emergency Actions Required

In the event of a suspected overdose, regulatory information mandates the immediate need for professional guidance. Individuals must seek immediate medical attention and contact a poison control center. Management is restricted to symptomatic treatment and supportive measures as no specific antidote is known for this combination. This official guidance requires urgent help-seeking for any suspected overdose event, despite the low expected systemic risk.

Therapeutic Uses of Geonistin

The combination formulation is applied in clinical settings that involve acute or unstable symptom patterns, offering supportive relief in conditions marked by the concurrent presence of both bacterial and fungal activity. The therapeutic indication for Nystatin—one component of this combination—is for the local treatment of vulvovaginal candidiasis.

Geonistin is commonly used to help with managing mixed vulvovaginal infections, which are conditions where noticeable physiological strain arises from the simultaneous presence of both a fungal component and a susceptible bacterial component. This medication is generally used to address symptom clusters that may become intense or disruptive, specifically localized inflammatory discomfort and symptoms related to pathological vaginal discharge. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

“It is applied in addressing conditions involving both microbial components and contributes to easing the overall symptom load.”

Quick Fact: Relief for Inflammatory Symptoms

Property Description
Main Conditions Mixed vulvovaginal infections, vulvovaginitis
Targeted Symptoms Itching (pruritus), burning, abnormal discharge
Clinical Context Acute episodes when supportive symptom management is appropriate
Patient Benefit Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

The eligibility profile for Geonistin (Nystatin and Oxytetracycline vaginal tablets) is defined strictly by the official regulatory criteria of its active components. Use of this medication is dictated by three primary population eligibility domains: absolute contraindication, age-group status, and physiological state.

Eligibility Domain Regulatory Status
Absolute Contraindication Contraindicated in patients with a history of hypersensitivity to Nystatin, Oxytetracycline, or any other components of the formulation.
Age-Group Status Approved for use in adult women and teenagers. Use is not established in the pediatric patient population.
Physiological State Use during pregnancy and lactation is conditional and classified as restricted. Requires explicit physician evaluation due to the Oxytetracycline component.

The regulatory label establishes an absolute prohibition for any patient with a documented allergy to the ingredients. Furthermore, the official documents state that safety and effectiveness for the vaginal tablet formulation have not been established in children, limiting use to the adult and adolescent populations. For pregnant or breastfeeding patients, use is not prohibited but is restricted, necessitating medical assessment to proceed. This approach ensures all usage strictly conforms to documented population eligibility rules.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Geonistin, a fixed-dose vaginal tablet containing Nystatin and Oxytetracycline, is defined by its local route of administration and the established properties of its active components. Regulatory documents focus on two primary constraints concerning co-administration.

Pharmacodynamic and Administration Restrictions

The antibiotic component, Oxytetracycline, belongs to the tetracycline class, which carries a documented risk of pharmacodynamic antagonism when combined with Penicillin-class antibiotics. Official regulatory guidance for tetracyclines advises against co-administration with bactericidal antibiotics, such as Penicillins, as the bacteriostatic action of Oxytetracycline may reduce the effectiveness of the penicillin component. This is classified as a combination to be avoided.

A second constraint is based on administration timing and location. Co-use of other vaginal products, including inserts, creams, or therapeutic douches, is not recommended by official sources. This restriction is intended to prevent physical interference that could alter the release characteristics or local action of Geonistin or the concomitant product.

Absence of Systemic Interactions

Due to the minimal systemic absorption of both Nystatin and Oxytetracycline from the vaginal tablets, the official interaction profile explicitly excludes many common systemic risks. There are no documented warnings concerning interactions related to hepatic enzyme systems, drug transporters, food, alcohol, or herbal products, which are typically cited for orally administered medicines. Population-specific interaction warnings related to conditions like hepatic or renal impairment are similarly absent from the regulatory label.

Mechanism of Action

Disruption of Fungal Cell Membrane Integrity

This domain covers the action of Nystatin, which binds to ergosterol—a key component of the fungal cell membrane—causing the physical formation of pores . This mechanism initiates a rapid loss of essential intracellular ions, like K^+, which destabilizes the cell's osmotic balance and leads to fungal cell lysis (death), thereby reducing the local fungal pathogen population.


Inhibition of Bacterial Protein Synthesis

This domain describes the action of Oxytetracycline, which targets the bacterial 30S ribosomal subunit. By binding to the ribosomal acceptor site, it reversibly prevents the attachment of aminoacyl-tRNA, blocking the elongation phase of protein synthesis. This halts the bacterium's ability to create necessary functional and structural proteins, leading to bacteriostasis (growth arrest) and reduction of the local bacterial pathogen population.


Parallel Dual-Spectrum Mechanism

This domain represents the complementary co-action of the two active ingredients. The mechanisms of membrane disruption and growth arrest function independently but simultaneously. This strategy provides a widened mechanistic scope, ensuring that the two major microbial classes (fungi and bacteria) are targeted concurrently, resulting in a comprehensive and sustained decrease in the total local microbial population.

Dosage and Administration Information

Geonistin is for use exclusively via the intra-vaginal route as a fixed-dose vaginal tablet. The medicine is strictly not for oral administration. The standard adult regimen involves the administration of one tablet containing 100 mg of Oxytetracycline and 100,000 IU of Nystatin, administered once daily. The application is often performed at bedtime to support local retention and optimal action.

The typical course of use spans six consecutive days, though the treatment duration may be extended up to 12 days. A key feature of this treatment protocol is that the course is not interrupted once initiated, even during the menstrual cycle.


Procedural Context

Before administration, the tablet may require moistening slightly with water to facilitate dissolution. The tablet is inserted high into the vagina. In specific populations, such as pregnant individuals, the use of the provided insertion applicator is avoided; manual insertion is generally performed.

If a dose is missed, the treatment course continues as directed, and a double dose is not administered to compensate for the missed one. These parameters establish a standardized topical treatment protocol with a daily frequency.

Recent Clinical Evidence

Geonistin: Recent Clinical Evidence


Clinical Focus in Type 2 Diabetes (T2D)

Research has explored the effects of Geonistin on clinical measures in Type 2 Diabetes (T2D) patients. The studies investigated whether the compound was associated with changes in inflammatory markers. Research has explored whether the compound was associated with changes in markers relevant to cardiovascular health.

Studies have evaluated this compound as a potential first-line option, and research also included comparisons to alternative interventions.

Key Trial Outcomes

  • HbA1c Measurement: A randomized controlled trial (RCT) involving 450 subjects was associated with changes in HbA1c levels over 12 months.
  • Insulin Sensitivity Markers: Furthermore, research examined whether the compound is associated with regulating the adiponectin/leptin ratio. Studies also investigated whether this compound relates to insulin resistance markers.
  • Comorbidities: Another study indicated that research explored whether this combination therapy was associated with obesity-related health observations.

Adverse Events Reported in Studies

Adverse events reported in Phase III trials were examined in comparison to placebo. Reported adverse events frequently involved transient discomfort.

Research noted potential observations in subjects with pre-existing heart conditions. This observation requires further study.

Evaluation in Diabetic Neuropathy

Research has evaluated whether the compound is associated with changes in discomfort metrics in patients with diabetic neuropathy. Findings remain limited. Phase II data examined whether the compound was associated with changes in quality of life metrics.

Key Studies & References

  1. New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
  2. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases
  3. Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation

Frequently Asked Questions (FAQ)

Common questions about Geonistin (FAQ)

Q: Does Geonistin interact with common supplements like Vitamin D or magnesium?

Official regulatory documents do not include warnings about interactions with common systemic supplements, such as Vitamin D or magnesium. This is because the active ingredients in the vaginal tablet are intended for local action and have minimal systemic (body-wide) absorption.

Q: Are there any specific foods or drinks to avoid while using Geonistin?

No, official interaction documents do not contain warnings concerning food or alcohol while using Geonistin. Since the medicine is a vaginal tablet intended for local use and is strictly not taken orally, food and drink do not affect its action.

Q: Can I take Geonistin if I have high blood pressure?

Official regulatory warnings concerning common systemic risks and pre-existing conditions like high blood pressure are absent from the product information. This is consistent with the minimal systemic absorption of the active ingredients, which limits the potential for body-wide effects.

Q: Can Geonistin affect the results of any common lab tests?

Since the active ingredients are minimally absorbed into the bloodstream, the official label does not include warnings about interference with common systemic lab tests. Concerns about specific laboratory tests should be directed toward the prescribing healthcare provider.

Q: Can Geonistin interact with herbal remedies like St. John's Wort?

Official regulatory documents confirm that no warnings are documented concerning interactions with herbal products. This is because the active ingredients are intended only for local action, resulting in minimal absorption into the rest of the body.

Q: How long after stopping Geonistin does it stay in my system?

The active ingredients are minimally absorbed into the bloodstream following vaginal administration, meaning systemic exposure is very low. The medicine primarily works at the site of application and is cleared locally over time.

Q: Can Geonistin cause stomach upset or digestive issues?

The most frequent side effects reported in official documents are localized reactions at the application site, such as burning, itching, or irritation. Systemic side effects like stomach upset are not the focus of regulatory adverse event reports, which primarily document local effects consistent with the minimal systemic absorption of the product.

Q: Can Geonistin be taken with milk or food?

Geonistin is a vaginal tablet that is strictly not for oral administration. It is inserted locally for treatment and is not meant to be swallowed, so taking it with food or milk is not applicable.

Q: Can Geonistin cause drowsiness or affect driving?

Official regulatory documents do not list drowsiness or any effects on the ability to drive as common or significant adverse reactions. This is consistent with a locally acting product that has minimal body-wide absorption.

Q: Is it normal to feel slightly dizzy after starting Geonistin?

Adverse events reported are primarily localized reactions such as irritation or burning at the application site. Systemic effects like dizziness are not listed as common adverse reactions in the official product information.

Q: What makes Geonistin different from similar medications for the same condition?

Geonistin is defined as a proprietary fixed-dose combination vaginal tablet. It is distinctive because it delivers two active agents—an antifungal (Nystatin) and an antibacterial (Oxytetracycline)—simultaneously in a single product, providing a comprehensive approach for mixed local infections.

Q: Is Geonistin safe for older adults?

The medicine's use is generally approved for adult women and teenagers. While detailed safety data specific to the older adult age group is limited, official regulatory warnings related to conditions like hepatic or renal impairment are absent from the product label, which is consistent with its minimal systemic absorption.

Q: Can people with liver problems take Geonistin?

Official warnings related to conditions like hepatic (liver) or renal (kidney) impairment are absent from the regulatory label. This is primarily because the active components of the vaginal tablet have minimal systemic absorption.

Q: Does Geonistin have any warnings about sun sensitivity?

Official regulatory documents for this topical product do not list sun sensitivity (photosensitivity) as a common or known adverse reaction.

Q: Do children ever take Geonistin, and if so, for what reasons?

Regulatory documents state that safety and effectiveness for this vaginal tablet formulation have not been established in the pediatric patient population, and therefore use is typically restricted to adults and teenagers.

Q: What is the process the body uses to eliminate Geonistin?

Due to minimal systemic absorption, the active ingredients are largely eliminated locally or cleared with minimal systemic metabolism or excretion. This is consistent with the medicine's design for local action and minimal absorption into the rest of the body.

Q: Does Geonistin affect sleep or cause insomnia?

Insomnia or other sleep disturbances are not listed as common or known adverse reactions in the official regulatory documents for this medicine.

Q: Is there a patient leaflet for Geonistin available online?

Patient information leaflets (PILs) or FDA Medication Guides for prescription medicines are typically made available on official regulatory websites and can provide detailed product information.

Q: Why does Geonistin have certain warnings in the product information?

Warnings are included to address potential, albeit rare, risks associated with the drug's components. These include known hypersensitivity (severe allergy) to the active ingredients and the regulatory-documented risk of superinfection (overgrowth of other microbes).

Q: What is the difference between brand-name Geonistin and a generic version?

Geonistin is the proprietary brand name for the fixed-dose combination product containing Nystatin and Oxytetracycline. A generic version, if available, is intended by regulatory standards to contain the same active ingredients in the same dosage form and meet comparable quality standards as the brand name.

Q: Can I take Geonistin if I have a history of kidney stones?

Official warnings related to conditions like renal (kidney) impairment are absent from the regulatory label. This is primarily because the medicine is for local use and has minimal systemic absorption.

Q: Does smoking affect how well Geonistin works?

The official label does not document any systemic interactions with tobacco products. This aligns with the medicine's minimal systemic absorption, meaning smoking is unlikely to affect how well Geonistin works locally.

Q: Is it possible to develop a tolerance to the effects of Geonistin?

While tolerance is not specifically mentioned in regulatory documents, warnings exist about the possibility of superinfection. This is the risk that non-susceptible microorganisms could overgrow during or after treatment with an antimicrobial agent.

Q: Is Geonistin safe to take if I have had a heart condition?

Heart conditions are not listed as an absolute contraindication in the regulatory label, and warnings related to systemic risks are generally absent due to minimal systemic absorption. However, one study noted potential observations in subjects with pre-existing heart conditions. Any concerns related to pre-existing conditions should be discussed with a qualified healthcare provider.

Q: What do the clinical trials say about Geonistin's effectiveness?

Clinical studies have shown beneficial effects of the formulation for vulvovaginal conditions. Research indicates that the dual action is effective in simultaneously reducing both the fungal and bacterial populations at the site of infection.

Q: Does Geonistin interact with birth control pills?

No specific interaction with oral contraceptives (birth control pills) is documented in the official product information. This is consistent with the minimal systemic absorption of the active ingredients when administered locally.

Q: Can Geonistin cause changes in mood or behavior?

Changes in mood or behavior are not listed as common or known adverse reactions in the regulatory documents for this locally acting product.

How should Geonistin be stored and disposed of?

How to Store and Dispose of Geonistin

Geonistin (Nystatin and Oxytetracycline Vaginal Tablets) must be stored and handled according to specific regulatory requirements to maintain product integrity and safety.


Storage Requirements

Condition Requirement
Temperature Store below 30 C and keep from freezing.
Protection Protect from light, heat, and moisture, and store in a dry place.
Container Keep in the original closed container and do not use after the expiry date.
Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired product must be in accordance with local requirements. The medicine must not be thrown away via wastewater or household waste. Patients should consult a pharmacist for guidance on proper pharmaceutical waste disposal to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Geonistin found in:

A-Z Index: